Spero therapeutics to present at cowen's 44th annual healthcare conference

Cambridge, mass., feb. 26, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) (spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that sath shukla, president and chief executive officer of spero therapeutics, will present and be available for one-on-one meetings at the cowen 44th annual healthcare conference, which is taking place march 4-6, 2024, at the boston marriott copley place in boston, ma. details are as follows:
SPRO Ratings Summary
SPRO Quant Ranking